Stereotactic Body Radiation Therapy in Patients with Limited Progressive Metastatic Cancers of the Breast and Lung

Print

Full Title

A Randomized Phase II Study Assessing the Efficacy of Local Ablative Radiation Therapy for Metastatic Breast and Lung Cancer Patients with Oligoprogressive Disease

Purpose

Triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) that spread to other parts of the body (metastasize) are usually treated with chemotherapy, immunotherapy, targeted therapies, and/or radiation therapy. In this study, researchers want to see if using stereotactic body radiosurgery (SBRT) plus standard therapy early, when a limited number of metastases are starting to grow, is more effective than standard therapy alone in patients with metastatic TNBC or NSCLC.

SBRT is a form of radiation therapy in which high doses of radiation are given very precisely, typically over five or fewer treatments. In this study, patients will be randomly assigned to receive SBRT followed by standard therapy, or standard therapy alone.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic TNBC or NSCLC that has continued to grow despite at least one prior regimen of systemic treatment (such as chemotherapy, immunotherapy, or targeted therapy) for metastatic disease.
  • Prior radiation therapy to the areas of metastasis is permitted.
  • Patients’ tumors may not have detectable molecular alterations in the EGFR or ALK proteins. Patients with those alterations may be able to receive other treatments that target those proteins.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. C. Jillian Tsai at 631-623-4268.

Protocol

18-431

Phase

II

Investigator

Co-Investigators